Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double‐Blind, Randomized, Placebo‐Controlled Trial

BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) reduce morbidity and mortality in heart failure with reduced ejection fraction (HFrEF). Their role in patients without heart failure, particularly in patients with coronary artery disease (CAD) and preserved EF, is still a matter of debate. H...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cardiol
Päätekijät: Sudano, Isabella, Naegele, Matthias, Roas, Susanne, Périat, Daniel, Frank, Michelle, Kouroedov, Alexey, Noll, Georg, Lüscher, Thomas F., Enseleit, Frank, Ruschitzka, Frank, Flammer, Andreas J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Wiley Periodicals, Inc. 2016
Aiheet:
Clinical Investigations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6490773/
https://ncbi.nlm.nih.gov/pubmed/26991772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22528
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia